Keith Wilson

Dr. Keith Wilson is the Chief Science Officer at Oxford BioTherapeutics. Keith has led research efforts at PDL BioPharma through the corporate transition into Facet Biotech, Abbott Laboratories, Abbvie, and now Oxford. He has led internal scientific and business reviews of pipeline portfolio and strategy leading to corporate directional change and has been responsible for implementation of new pipeline strategies. He was a Postdoctoral Fellow at Stanford University and later the Director of Computational Biology and Genomics at EOS Biotechnology and PDL BioPharma. Dr. Wilson holds Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science Uniersity.